>Mercado europeu de tratamento do linfedema, por tipo de tratamento (terapia de compressão, cirurgia, terapia medicamentosa, terapia laser e outros), tipo (linfedema primário e linfedema secundário), área afetada (genital, extremidade inferior, extremidade superior e outros) , faixa etária (adulto e Geriátrica), Via de Administração (Oral, Injetável e Outros), Utente Final (Hospitais, Centros Cirúrgicos de Ambulatório, Clínicas de Especialidades e Outros), Canal de Distribuição (Concurso Direto, Farmácias e Outros), País ( Alemanha, França, Reino Unido , Hungria, Lituânia, Áustria, Irlanda, Noruega, Polónia, Itália, Espanha, Suíça, Países Baixos, Bélgica, Rússia, Turquia e resto da Europa) Tendências e previsões da indústria para 2029
Análise de Mercado e Insights: Mercado Europeu de Tratamento do Linfedema
Espera-se que o mercado europeu de tratamento do linfedema ganhe um crescimento significativo no período de previsão de 2022 a 2029. A Data Bridge Market Research analisa que o mercado europeu de tratamento do linfedema está a crescer com um CAGR de 7,8% no período de previsão de 2022 a 2029 e prevê-se que atinja os 458,39 milhões de dólares até 2029, contra 256,09 milhões em 2022. O aumento dos gastos em saúde e a escalada em inovação e tecnologias são impulsionadores esperados para o crescimento do mercado no período de previsão.
O linfedema refere-se ao inchaço que geralmente ocorre nas extremidades superiores e inferiores. Por vezes, ambos os braços e pernas incham. O linfedema é mais comumente causado pela remoção ou lesão dos gânglios linfáticos como parte do tratamento do cancro. Resulta de um bloqueio no sistema linfático, que faz parte do sistema imunitário. Resulta de um sistema linfático danificado e pode causar infeções, desfiguração, dor debilitante e incapacidade. Não existe cura para o linfedema.
O tratamento do linfedema envolve múltiplas terapêuticas em vez do tratamento padrão, uma vez que os doentes ficam insatisfeitos ou não se curam com o tratamento convencional do linfedema. Abordam o tratamento alternativo que oferece um maior controlo sobre as decisões de cuidados de saúde, sendo que as alternativas são consideradas mais compatíveis com o sistema de saúde do doente.
O linfedema pode ocorrer após qualquer cancro ou o seu tratamento que afete a drenagem dos gânglios linfáticos. Foi relatado que ocorre dentro de alguns dias e até 30 anos após o tratamento do cancro da mama. Os tratamentos do linfedema em fase inicial são as terapias, as cirurgias e o transplante linfovenoso, entre outros. Mas não existe uma cura permanente para o linfedema.
Um número crescente de pessoas é afetado por linfedema, o que exige um tratamento altamente eficaz e avançado para minimizar o risco durante o tratamento. Os sistemas de saúde necessitam de terapias altamente avançadas para inúmeras doenças do linfedema durante o tratamento dos pacientes. Por conseguinte, os principais players do mercado estão altamente focados em lançamentos e aprovações de produtos. Além disso, o governo e as entidades reguladoras estão a apoiar os participantes do mercado em virtude da aprovação do produto.
A procura pelo tratamento do linfedema aumentou rapidamente em todo o mundo durante a última década devido ao aumento da incidência de doentes com linfedema.
Prevê-se que o elevado custo do tratamento e os efeitos secundários adversos associados ao tratamento dificultem o crescimento do mercado no período projetado.
Iniciativas estratégicas dos players do mercado, aumento dos gastos em saúde, aumento do número de fabricantes de medicamentos atuam como uma oportunidade para este mercado e deverão impulsionar o crescimento do mercado.
Espera-se que nenhuma cura permanente para o linfedema seja o principal desafio para o crescimento futuro do mercado europeu de tratamento do linfedema.
O relatório de mercado do tratamento do linfedema na Europa fornece detalhes da quota de mercado, novos desenvolvimentos e análise do pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações do mercado , aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um Analyst Brief, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Mercado europeu de tratamento do linfedema e dimensão do mercado
O mercado europeu de tratamento do linfedema está segmentado com base no tipo de tratamento, por tipo, por área afetada, por faixa etária, por via de administração, por utilizador final, por canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no tipo de tratamento, o mercado europeu de tratamento do linfedema está segmentado em terapia de compressão , cirurgia, terapia medicamentosa, terapia laser e outros. Em 2022, prevê-se que o segmento da terapia de compressão domine o mercado devido ao aumento da prevalência do linfedema entre a população-alvo.
- Com base no tipo, o mercado europeu de tratamento do linfedema está segmentado em linfedema primário e linfedema secundário. Em 2022, prevê-se que o segmento do linfedema secundário domine o mercado devido à crescente consciencialização da doença.
- Com base na área afetada, o mercado europeu de tratamento do linfedema é segmentado genital, extremidade inferior e extremidade superior. Em 2022, prevê-se que o segmento das extremidades inferiores domine o mercado de um grande grupo de doentes com linfedema das extremidades inferiores.
- Com base na faixa etária, o mercado europeu de tratamento do linfedema está segmentado em adulto e geriátrico. Em 2022, prevê-se que o segmento adulto domine o mercado devido ao aumento dos lançamentos de produtos por parte dos principais players do mercado.
- Com base na via de administração, o mercado europeu de tratamento do linfedema está segmentado em oral, injetável e outros. Em 2022, prevê-se que o segmento oral domine o mercado, pois é o modo de administração mais eficaz.
- Com base no utilizador final, o mercado europeu de tratamento do linfedema está segmentado em hospitais, centros de cirurgia ambulatória, clínicas especializadas e outros. Em 2022, prevê-se que o segmento hospitalar domine o mercado devido ao aumento dos lançamentos de produtos por parte dos principais players do mercado.
- Com base no canal de distribuição, o mercado europeu de tratamento do linfedema está segmentado em licitação direta, farmácias e outros. Em 2022, prevê-se que o segmento das lojas de farmácias domine o mercado devido ao aumento das parcerias entre distribuidores.
Análise a nível de país do mercado europeu de tratamento do linfedema
O mercado europeu de tratamento do linfedema é analisado e a informação sobre a dimensão do mercado é fornecida com base, por tipo de tratamento, por tipo, por área afetada, por faixa etária, por via de administração, por utilizador final, por canal de distribuição.
Os países abrangidos no relatório do mercado europeu de tratamento do linfedema são a Alemanha, França, Reino Unido, Hungria, Lituânia, Áustria, Irlanda, Noruega, Polónia, Itália, Espanha, Rússia, Turquia, Bélgica, Países Baixos, Suíça e resto da Europa.
Espera-se que a Alemanha domine o mercado europeu de tratamento do linfedema devido ao aumento do financiamento governamental na região.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e a disponibilidade das marcas europeias e os desafios enfrentados devido à concorrência grande ou escassa das marcas locais e nacionais, o impacto dos canais de vendas são considerados, ao mesmo tempo que fornecem uma análise de previsão dos dados do país.
O aumento dos gastos em saúde e a escalada em inovações e tecnologias no mercado europeu de tratamento do linfedema estão a criar novas oportunidades para os participantes do mercado europeu de tratamento do linfedema
Espera-se que o segmento da região do mercado europeu de tratamento do linfedema na Alemanha cresça com a taxa mais elevada e esteja a dominar a região no período de previsão de 2022 a 2029 devido ao aumento do financiamento governamental.
O mercado europeu de tratamento do linfedema também fornece análises de mercado detalhadas para o crescimento de cada país numa indústria específica com as vendas do mercado europeu de tratamento do linfedema, impacto do avanço no mercado europeu de tratamento do linfedema e mudanças nos cenários regulamentares com o seu apoio ao mercado europeu de tratamento do linfedema.
Análise do panorama competitivo e da quota de mercado do tratamento do linfedema na Europa
O panorama competitivo do mercado europeu de tratamento do linfedema fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura do produto e respiração, domínio da aplicação e curva da linha de vida da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado europeu de tratamento do linfedema.
Os principais participantes abordados no relatório são a Bio Compression Systems, Inc., Lohmann & Rauscher, Mego Afek ltd, SIGVARIS, Tactile Systems Technology Inc., medi GmbH & Co. Julius Zorn GmbH, Cardinal Health, Inc., Smith & Nephew plc, ThermoTek, Huntleigh Healthcare Limited, Herantis Pharma Plc. são participantes no mercado europeu de tratamento do linfedema. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos lançamentos de produtos e acordos são também iniciados por empresas de todo o mundo, que estão a acelerar ainda mais o mercado europeu de tratamento do linfedema.
Por exemplo,
- Em março de 2021, a Herantis Pharma Plc anunciou que os resultados dos ensaios clínicos do seu estudo de Fase II que investiga a terapia genética para a Lymfactina, para o tratamento do Linfedema Relacionado com o Cancro da Mama (BCRL), eram inconclusivos. A linfactina é uma terapia genética única, uma proteína endógena responsável por impulsionar o crescimento e a regeneração dos vasos linfáticos. Este produto em pipeline ajudou a empresa a aumentar o seu alcance no mercado de tratamento do linfedema.
- Em setembro de 2020, a Paul Hartmann AG estabeleceu parcerias com o Apollo Hospitals Group na Índia e o West China Hospital para se concentrar na operação de clínicas de tratamento de feridas e ambulâncias, formação médica e produtos e serviços. Esta etapa ajudou a empresa a abrir as suas asas no mercado Ásia-Pacífico.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE LYMPHEDEMA TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S ANALYSIS
4.2 PORTER'S MODEL
5 PIPELINE ANALYSIS FOR EUROPE LYMPHEDEMA TREATMENT MARKET
6 EPIDEMIOLOGY
7 REGULATORY GUIDELINES FOR EUROPE LYMPHEDEMA TREATMENT MARKET
7.1 U.S.
7.2 EUROPE
7.3 INDIA
7.4 MEXICO
7.5 CANADA
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES EUROPELY
8.1.2 INCREASE IN THE PREVALENCE OF CANCERS
8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES
8.1.4 MULTIPLE THERAPIES
8.2 RESTRAINTS
8.2.1 HIGH COST OF TREATMENT
8.2.2 LACK OF AWARENESS ABOUT THE DISEASE
8.3 OPPORTUNITIES
8.3.1 DRUG APPROVALS
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.4 CHALLENGES
8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA
8.4.2 DIFFICULT REIMBURSEMENT
9 IMPACT OF COVID-19 ON THE EUROPE LYMPHEDEMA TREATMENT MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
9.5 CONCLUSION
10 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE
10.1 OVERVIEW
10.2 COMPRESSION THERAPY
10.2.1 BY PRODUCT
10.2.1.1 COMPRESSION PUMPS
10.2.1.2 COMPRESSION GARMENTS
10.2.1.2.1 COMPRESSION STOCKINGS
10.2.1.2.2 COMPRESSION SLEEVES
10.2.1.2.3 OTHERS
10.2.1.3 COMPRESSION BANDAGES & WRAPS
10.2.1.4 OTHERS
10.2.2 BY TECHNIQUE
10.2.2.1 STATIC COMPRESSION THERAPY
10.2.2.2 DYNAMIC COMPRESSION THERAPY
10.3 SURGERY
10.3.1 LYMPHOVENOUS TRANSPLANT
10.3.2 LYMPHATICOVENOUS ANASTOMOSIS
10.3.3 LIPOSUCTION
10.3.4 OTHERS
10.4 DRUG THERAPY
10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
10.4.2 RETINOIDS
10.4.3 ANTIBIOTICS
10.4.4 OTHERS
10.5 LASER THERAPY
10.6 OTHERS
11 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 SECONDARY LYMPHEDEMA
11.3 PRIMARY LYMPHEDEMA
11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE)
11.3.2 CONGENITAL LYMPHEDEMA
11.3.3 LYMPHEDEMA TARDA
12 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA
12.1 OVERVIEW
12.2 LOWER EXTREMITY
12.3 UPPER EXTREMITY
12.4 GENITALIA
13 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.3 GERIATRIC
13.4 PEDIATRIC
14 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.3 INJECTABLE
14.4 TOPICAL
15 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 SPECIALTY CLINICS
15.4 AMBULATORY SURGICAL CENTERS
15.5 OTHERS
16 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 PHARMACY STORES
16.3 DIRECT TENDER
16.4 OTHERS
17 EUROPE LYMPHEDEMA TREATMENT MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 UNITED KINGDOM
17.1.4 ITALY
17.1.5 RUSSIA
17.1.6 SPAIN
17.1.7 TURKEY
17.1.8 NETHERLANDS
17.1.9 SWITZERLAND
17.1.10 BELGIUM
17.1.11 POLAND
17.1.12 AUSTRIA
17.1.13 HUNGARY
17.1.14 NORWAY
17.1.15 IRELAND
17.1.16 LITHUANIA
17.1.17 REST OF EUROPE
18 EUROPE LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYIS
20 COMPANY PROFILE
20.1 TACTILE MEDICAL
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.1.6 CLINICAL TRIAL:
20.2 ESSITY (BSN MEDICAL GMBH)
20.2.1 COMPANY SNAPSHOT
20.2.2 COMPANY SHARE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENT
20.3 3M
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.3.6 NEW BUSINESS SEGMENT
20.3.7 ACQUISITION
20.4 CARDINAL HEALTH
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.5 LOHMANN & RAUSCHER GMBH & CO. KG
20.5.1 COMPANY SNAPSHOT
20.5.2 COMPANY SHARE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 AIROS MEDICAL, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.6.4 PRODUCT LAUNCH:
20.7 AVET PHARMACEUTICALS INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 BIOCOMPRESSION SYSTEMS
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.8.4 AGREEMENT
20.9 CONVATEC INC.
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT
20.1 HERANTIS PHARMA PLC
20.10.1 COMPANY SNAPSHOT
20.10.2 RECENT DEVELOPMENT
20.11 HUNTLEIGH HEALTHCARE LIMITED
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 JUZO
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 KOYA MEDICAL
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.13.4 APPROVAL
20.14 MEDI GMBH & CO. KG
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 MEGO AFEK LTD
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.15.4 APPLICATION LAUNCH:
20.16 PAUL HARTMANN AG
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENTS
20.17 SANYLEG SRL A SOCIO UNICO
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
20.18 SIGVARIS GROUP
20.18.1 COMPANY SNAPSHOT
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENTS
20.18.4 PRODUCT LAUNCHES:
20.19 SMITH +NEPHEW
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENT
20.2 THERMOTEK
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Lista de Tabela
TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT:
TABLE 2 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 3 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2020-2029 (USD MILLION)
TABLE 4 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 EUROPE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 6 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 11 EUROPE LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 18 EUROPE LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 22 EUROPE ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 EUROPE HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 35 EUROPE PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 40 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 41 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 42 EUROPE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 43 EUROPE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 44 EUROPE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 46 EUROPE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 48 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 49 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 50 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 53 GERMANY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 54 GERMANY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 55 GERMANY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 56 GERMANY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 57 GERMANY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 58 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 GERMANY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 GERMANY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 61 GERMANY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 62 GERMANY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 63 GERMANY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 GERMANY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 66 FRANCE COMPRESSION THERAPY LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 67 FRANCE COMPRESSION THERAPY LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 68 FRANCE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 69 FRANCE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 70 FRANCE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 71 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 FRANCE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 FRANCE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 74 FRANCE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 75 FRANCE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 76 FRANCE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 77 FRANCE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 78 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 79 UNITED KINGDOM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 80 UNITED KINGDOM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 81 UNITED KINGDOM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 82 UNITED KINGDOM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 83 UNITED KINGDOM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 84 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 UNITED KINGDOM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 87 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 88 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 89 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 90 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 91 ITALY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 92 ITALY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 93 ITALY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 94 ITALY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 95 ITALY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 96 ITALY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 97 ITALY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 ITALY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 ITALY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 100 ITALY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 101 ITALY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 102 ITALY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 103 ITALY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 104 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 105 RUSSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 106 RUSSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 107 RUSSIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 108 RUSSIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 109 RUSSIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 110 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 RUSSIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 113 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 114 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 115 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 118 SPAIN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 119 SPAIN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 120 SPAIN COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 121 SPAIN SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 122 SPAIN DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 123 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 SPAIN PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 SPAIN LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 126 SPAIN LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 127 SPAIN LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 128 SPAIN LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 129 SPAIN LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 130 TURKEY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 131 TURKEY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 132 TURKEY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 133 TURKEY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 134 TURKEY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 135 TURKEY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 136 TURKEY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 TURKEY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 TURKEY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 139 TURKEY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 140 TURKEY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 141 TURKEY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 142 TURKEY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 143 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 144 NETHERLANDS COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 145 NETHERLANDS COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 146 NETHERLANDS COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 147 NETHERLANDS SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 148 NETHERLANDS DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 149 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 NETHERLANDS PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 152 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 153 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 154 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 155 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 156 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 157 SWITZERLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 158 SWITZERLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 159 SWITZERLAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 160 SWITZERLAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 161 SWITZERLAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 162 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 163 SWITZERLAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 165 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 166 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 167 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 168 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 169 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 170 BELGIUM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 171 BELGIUM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 172 BELGIUM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 173 BELGIUM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 174 BELGIUM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 175 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 BELGIUM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 178 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 179 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 180 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 181 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 182 POLAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 183 POLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 184 POLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 185 POLAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 186 POLAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 187 POLAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 188 POLAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 189 POLAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 POLAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 191 POLAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 192 POLAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 193 POLAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 194 POLAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 195 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 196 AUSTRIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 197 AUSTRIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 198 AUSTRIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 199 AUSTRIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 200 AUSTRIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 201 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 202 AUSTRIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 204 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 205 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 206 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 207 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 208 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 209 HUNGARY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 210 HUNGARY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 211 HUNGARY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 212 HUNGARY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 213 HUNGARY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 214 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 215 HUNGARY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 216 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 217 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 218 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 219 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 220 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 221 NORWAY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 222 NORWAY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 223 NORWAY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 224 NORWAY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 225 NORWAY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 226 NORWAY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 227 NORWAY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 228 NORWAY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 229 NORWAY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 230 NORWAY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 231 NORWAY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 232 NORWAY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 233 NORWAY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 234 IRELAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 235 IRELAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 236 IRELAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 237 IRELAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 238 IRELAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 239 IRELAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 240 IRELAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 241 IRELAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 IRELAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 243 IRELAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 244 IRELAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 245 IRELAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 246 IRELAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 247 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 248 LITHUANIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 249 LITHUANIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 250 LITHUANIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 251 LITHUANIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 252 LITHUANIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 253 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 254 LITHUANIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 255 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 256 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 257 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 258 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 259 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 260 REST OF EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
Lista de Figura
FIGURE 1 EUROPE LYMPHEDEMA TREATMENT MARKET : SEGMENTATION
FIGURE 2 EUROPE LYMPHEDEMA TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 EUROPE LYMPHEDEMA TREATMENT MARKET : DROC ANALYSIS
FIGURE 4 EUROPE LYMPHEDEMA TREATMENT MARKET: EUROPE VS REGIONAL ANALYSIS
FIGURE 5 EUROPE LYMPHEDEMA TREATMENT MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LYMPHEDEMA TREATMENT MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE LYMPHEDEMA TREATMENT MARKET : DBMR MARKET POSITION GRID
FIGURE 8 EUROPE LYMPHEDEMA TREATMENT MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE LYMPHEDEMA TREATMENT MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE LYMPHEDEMA TREATMENT MARKET : SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE EUROPE LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LYMPHEDEMA TREATMENT MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE LYMPHEDEMA TREATMENT MARKET AND ASIA-PACIFIC TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE LYMPHEDEMA TREATMENT MARKET
FIGURE 15 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2021
FIGURE 16 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2020-2029 (USD MILLION)
FIGURE 17 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 18 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 19 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2021
FIGURE 20 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 21 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 22 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2021
FIGURE 24 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2020-2029 (USD MILLION)
FIGURE 25 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2022-2029)
FIGURE 26 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE
FIGURE 27 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2021
FIGURE 28 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2020-2029 (USD MILLION)
FIGURE 29 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 30 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 31 EUROPE LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 32 EUROPE LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 33 EUROPE LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 34 EUROPE LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 EUROPE LYMPHEDEMA TREATMENT MARKET: BY END USER, 2021
FIGURE 36 EUROPE LYMPHEDEMA TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 37 EUROPE LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 EUROPE LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 EUROPE LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 EUROPE LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 41 EUROPE LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL ,CAGR (2022-2029)
FIGURE 42 EUROPE LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 EUROPE LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 44 EUROPE LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 45 EUROPE LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 EUROPE LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 47 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE (2022-2029)
FIGURE 48 EUROPE LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
